The pace of Redwood Pharma development activities surrounding the company’s dry eye ophthalmic therapy RP101 has been high during the fall of 2016. Our spring IPO on AktieTorget where the company raised SEK 15 million has intensified development of RP101 while the firm has not experienced any setbacks. This has enabled the company to participate in several international forums to generate interest in the firm’s development project and expand its valuable network.
In SwedenBio’s latest report of the Swedish pharmaceutical industry for 2016 the organization highlighted development projects within women’s health. Among the 17 projects mentioned was Redwood Pharma’s development project RP101 for the treatment of chronic dry eye disease in post-menopausal women.
Evidence that Redwood Pharma’s development project has garnered was confirmed at various international, biotechnology and pharmaceutical development conferences attended by the company during the fall. By attending conferences, the company is able to generate more interest and awareness about our development project and to expand our valuable network of contacts for future licensing our trade sale of it.
Attending conferences continues. Redwood Pharma will participate in meetings in connection with the JPMorganChase Healthcare Conference in San Francisco between January 9-12. In parallel with the conference, the US biotechnology industry trade organization BIO will be organizing facilities for meetings between development companies like Redwood Pharma and possible investors and representatives of large pharmaceutical firms.
“A lot has happened in the company during 2016 which again confirms the large potential of RP101 and the IntelliGel platform. We are now preparing for the start of toxicological testing of RP101 at the beginning of next year and for our clinical Phase II trial later in 2017”, says CEO Martin Vidaeus.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel®, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.
Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information see: www.redwoodpharma.com